INTRODUCTION
The syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) is a life-threatening subset of pre-eclampsia that assumed its own identity as a disease in 1982. 1 The disease is characterized by a microangiopathic hemolytic anemia that seems to be only quantitatively different from that of pre-eclampsia even though it is mostly targeted to the liver, at least initially. As the disease progresses, however, the involvement of multiple other organs and systems is responsible for the numerous clinical manifestations such as renal failure, ascites, gastrointestinal complications, acute respiratory distress syndrome (ARDS), visual difficulties, and multiorgan failure. The coagulation system is involved early on in a local, low-grade intravascular coagulation because of the microangiopathy, but it can progress to disseminated intravascular coagulation (DIC) in up to 55% of patients. 2 Several management options have been proposed for patients with HELLP syndrome. Conservative management with supportive measures has been suggested in the less severe cases to allow fetal maturity. 3 Steroids and anticoagulants are two other forms of therapy proposed for this complication of pregnancy. 4, 5 However, delivery is still the standard of care for most patients with HELLP syndrome.
The use of heparin has been proposed for patients with pre-eclampsia, HELLP syndrome, and DIC. [5] [6] [7] [8] [9] [10] Nevertheless, most authors oppose the use of heparin despite the fact that only a few studies have reported an adverse effect of heparin for such complications of pregnancy. 11, 12 At the University of Florence, we have used heparin in postpartum patients who developed HELLP syndrome with or without DIC since 1990. The aim of this study was to assess the outcome of patients diagnosed with HELLP syndrome and treated with heparin in the immediate puerperium compared to that of patients managed with supportive therapy during the same period of time at the University of Virginia (UVA), Charlottesville, VA.
MATERIAL AND METHODS
This study included 16 consecutive patients with HELLP syndrome who were admitted at the University of Florence from January 1990 to December 1997. Five more patients with this diagnosis, but with previous medical complications such as cardiovascular and renal diseases, and hemorrhagic diatheses, were excluded from the study. In all, 16 more patients, matching the first ones by race, gestational age, and severity of the syndrome, were recruited among those who presented to the University of Virginia Hospital in Charlottesville, VA, with a diagnosis of HELLP syndrome during the same period of time. This group of patients was managed with supportive therapy only. The severity of the syndrome was quantified by the values reached by liver enzymes, markers of hemolysis, platelet number, and blood pressure. Gestational age was based on menstrual dates in association with ultrasonographic examination performed in the first trimester.
Diagnosis of HELLP syndrome was made when platelets r100,000/mm 3 , aspartate aminotransferase (AST) and alanine aminotransferase (ALT) Z70 U/l, and objective signs of microangiopathic hemolysis (burr cells, schistocytes) were present. 13 A peripheral blood smear was not performed for all patients, but a lactate dehydrogenase (LDH) value Z600 U/l, hyperbilirubinemia (Z1.2 mg/dl), and acute anemia were also considered signs of hemolysis. 14 The following studies were performed every 6 hours until normalization of the laboratory parameters was achieved: hematocrit, platelets, fibrinogen, antithrombin III activity, D-dimer, prothrombin time (PT), partial thromboplastin time (PTT), LDH, AST, ALT, total and direct bilirubin, and renal function tests.
Diagnosis of DIC was made when three or more parameters of the following scoring system were present: platelet count r100,000/mm 3 , PT r70%, PTT Z40 seconds, antithrombin III r80%, fibrinogen r300 mg/dl, either fibrinogen degradation products Z40 mg/dl or D-dimer test Z800 with the latex essay determination (specific for detection of fibrin degradation products and more reliable for the presence of DIC). 15, 16 Nine patients of the Florence group and 13 of UVA group received intramuscular (IM) betamethasone 12 mg every 24 hours for 2 days because <34 weeks' gestation. All the hypertensive patients (systolic blood pressure Z140 mmHg, diastolic Z90 mmHg) received intravenous (IV) magnesium sulfate to prevent seizures. Antihypertensive therapy when blood pressure Z160/105 mmHg consisted in bolus doses of hydralazine, 5 to 10 mg, or oral nifedipine, 10 to 20 mg, according to the physician's preference.
Following the diagnosis of HELLP syndrome, the patients were stabilized and underwent a cesarean delivery, according to both management protocols. All 16 patients form Florence were admitted to the intensive care unit (ICU) after delivery. In the ICU, all were treated initially with heparin 5000 IU subcutaneous (SQ) every 12 hours. A dose of 15,000 IU IV in continuous infusion every 24 hours was used in the nine patients who developed DIC. Therapy with heparin was administered until there was evidence of recovery of the coagulation parameters. Additionally, patients with DIC received intravenous antithrombin III (1000 IU/day until antithrombin activity was above 80%), and fresh frozen plasma (FFP). The 16 patients from UVA were transferred to the recovery room soon after surgery and given supportive care only.
Patients were transfused with red blood cells if they were symptomatic (dizziness, tachycardia) or blood hemoglobin was below 8 g/dl.
Data are presented as the mean±standard deviation (SD) or the median with range. Statistical comparisons were performed with paired Fisher's exact test and Mann-Whitney U-test as indicated. A p-value less than 0.05 was considered significant.
RESULTS
The clinical characteristics of the two groups of patients are presented in Table 1 . The only difference between the groups was maternal age. Two out of 16 (12.5%) patients for each group had normal blood pressure. Totally, 14 patients from the Florence group and 15 from the UVA group underwent cesarean delivery, respectively.
In the Florence group, 14 patients were diagnosed with HELLP syndrome prior to delivery. Among them, eight were primigravidas and six multigravidas. Two developed eclamptic seizures prior to Table 2 . In the Florence group, patients remained in ICU after delivery for 3.5 days (median; range 2 to 28 days). Nine of them developed DIC (56%) in the absence of placental abruption, four of them had received steroids IM for lung maturity prior to delivery. Patients with DIC received IV heparin for 4 days (median; range 2 to 12 days); the seven patients who did not develop DIC received subcutaneous heparin for 7 days.
Overall, 12 patients (nine of them also fresh frozen plasma) in group 1 and eight in group 2 required serial red blood cell transfusions. Table 3 shows the outcome of patients with DIC in group 1. Six of them had hemorrhage that was controlled both with medical and surgical interventions. In this group of women, a total of 12 surgical procedures were performed. Administration of FFP to patients with hemorrhage was followed by recovery from the coagulopathy and no need for subsequent surgery in two patients (Nos. 8,9). All patients with DIC not complicated by hemorrhage (Nos. 1, 3, 6) experienced gradual resolution of the coagulopathy with medical therapy. Plasmapheresis was performed in one patient (No. 3) because of deteriorating microangiopathic hemolytic anemia needing repetitive red blood cell transfusions, and deteriorating renal function. This patient developed acute renal failure that required dialysis on the second postpartum day. She subsequently improved and was discharged home on postpartum day No. 23 with no need for further dialysis.
The only patient who developed DIC in the UVA group in the absence of placental abruption, had the postpartum complicated by pulmonary edema. She was in the hospital for 10 days. Another patient of this group developed a subcutaneous effusion at the surgical incision site and a retroperitoneal hematoma. She was discharged home on the 11th day after delivery in stable conditions.
Of the 16 fetuses born in Florence, one died in utero at 26 weeks' gestation and was delivered by cesarean delivery after a failed attempt of vaginal delivery. One infant was delivered at 26 weeks and died after 27 days of life. A third infant was delivered at 29 weeks and died after 3 days of life. Both infants died because of respiratory complications. In total, 13 infants were discharged home in stable conditions.
All the 16 infants born at UVA were discharged home in stable conditions.
COMMENT
HELLP syndrome is a disease of unknown etiology for which the ultimate treatment is delivery. Even though involving the microcirculation of specific organs, in some women the process becomes systemic and fulminant with a mortality rate of 1% in tertiary centers. 17, 18 Also, it has been suggested that intravascular hemolysis and acute liver disease may play an important role by triggering the development of systemic DIC. 16 In our study, we compared two groups of patients that were different only by maternal age. The various manifestations of HELLP syndrome were similar in all patients, and we do not believe the adverse outcome in the Florence group was impacted solely by the older age.
The prevalence of DIC in patients with HELLP syndrome ranges from 4 to 55%. Weinstein studied 26 cases of HELLP syndrome. He reported that 4% of his patients (1/26) developed DIC. 1 Van Dam et al. 2 in their study reported that 55% of the patients with HELLP syndrome (10/18) developed DIC in the absence of placental abruption. Sibai et al. 19 found 38% incidence of DIC in their series (42/112). In a subsequent study, Sibai et al. reported 442 patients with HELLP syndrome. In that series the rate of DIC was 21% (92/ 442). The incidence of cesarean hysterectomies was 1.1% (5/442), whereas 0.7% of the patients (3/442) underwent postpartum laparotomies because of retroperitoneal hematomas and external bleeding. Two of the three patients were receiving heparin to treat DIC. 17 Martin et al. 20 reported a series of 158 cases of HELLP syndrome managed with supportive therapy except for 11 gravidas (7%) who underwent plasma exchange. In their series there were no postpartum complications that led to further surgical intervention. In two following studies, the same authors proposed the use of dexamethasone for the management of HELLP syndrome during the postpartum period. 21, 22 The authors reported a faster resolution and less complications of HELLP syndrome in 63 patients diagnosed either during pregnancy or after delivery and treated with dexamethasone, when compared to a control group of patients with the same disease but treated with supportive therapies other than steroids. More importantly, there were no postpartum surgical procedures performed because of bleeding. In a more recent publication, Martin et al. 18 reported 501 cases of HELLP syndrome with platelets below 100,000. The authors reported 12.2% (61/501) cases of DIC complicating HELLP syndrome in the absence of placental abruption, and bleeding complications in 85.2% of them (52/61).
Heparin therapy has been used in several studies for the treatment of pre-eclampsia with hemolysis and thrombocytopenia. The results of its usefulness have been controversial, but in spite of the theoretical risk of bleeding with heparin therapy, some studies have not reported an increased rate of hemorrhagic complications. [5] [6] [7] [8] Butler et al. reported four cases of ''toxemia of pregnancy'' treated with heparin. The disease resolved only after delivery in all patients, but there was no occurrence of bleeding. 6 Howe et al. 7 reported three cases of ''severe pre-eclampsia'' complicated by DIC in which heparin and antiplatelet therapy (dipyridamole) were used and no bleeding complications occurred. Brain et al. 5 reported two cases of ''hemolysis and thrombocytopenia in pre-eclampsia'' in which heparin therapy was successfully used in order to improve maternal disease. Goldsmith et al. 8 treated one patient with ''fulminating toxaemia of pregnancy'' with hemodialysis and intravenous heparin and prolonged pregnancy for 5 weeks, allowing the delivery of a healthy infant. In all these cases, no bleeding complication was reported following heparin administration.
Other authors have reported a beneficial effect of heparin therapy in pregnant patients with DIC complicating intrauterine fetal death. 23 Romero et al. 24 found that heparin therapy would lead to reversal of the consumption coagulopathy with elevation of the fibrinogen level that would result in the uneventful prolongation of pregnancy for several weeks.
We used heparin in the postpartum period for patients who developed HELLP syndrome with or without DIC during the period in which it was uncertain if heparin was useful. We have encountered important bleeding complications that initially we attributed to a more severe presentation of the HELLP syndrome. However, when the cases were considered together and our outcome compared to the outcome of other studies, the complications could not be explained only by the natural history of the illness, In total, 56% of our patients developed DIC. The prenatal administration of betamethasone to the patients <34 weeks seemed not to have any impact on the severity of HELLP syndrome. Totally, 12 laparotomies were performed to control bleeding in this group of patients. In all, 31% of patients underwent hysterectomy. Overall, 19% of patients developed acute renal failure probably secondary to the severity of HELLP syndrome and acute anemia. Our complications were much higher than those reported with general supportive therapies. Heparin certainly played an important role in those complications. We speculate that in our study population, two combined factors determined the increased risk of bleeding following heparin: the microangiopathy of the disease that leads to endothelial damage, and the anatomical discontinuation of the vessels associated with the surgical intervention.
Heparin for patients with HELLP syndrome and/or DIC is not currently used in the United States, but it is still in use in many other countries worldwide. Our results show that the use of heparin should be discouraged for patients with HELLP syndrome because of the high bleeding complications due to this therapy. Adverse Outcome using Heparin for HELLP Syndrome Detti et al.
